Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.

Scoriels L, Salek RM, Goodby E, Grainger D, Dean AM, West JA, Griffin JL, Suckling J, Nathan PJ, Lennox BR, Murray GK, Bullmore ET, Jones PB.

Transl Psychiatry. 2015 Mar 31;5:e540. doi: 10.1038/tp.2015.26.

2.

In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.

Wijtenburg SA, Yang S, Fischer BA, Rowland LM.

Neurosci Biobehav Rev. 2015 Apr;51:276-95. doi: 10.1016/j.neubiorev.2015.01.007. Epub 2015 Jan 19. Review.

3.

Glutamate-mediated excitotoxicity in schizophrenia: a review.

Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A.

Eur Neuropsychopharmacol. 2014 Oct;24(10):1591-605. doi: 10.1016/j.euroneuro.2014.07.015. Epub 2014 Aug 1. Review.

4.

The neurobiology and treatment of first-episode schizophrenia.

Kahn RS, Sommer IE.

Mol Psychiatry. 2015 Feb;20(1):84-97. doi: 10.1038/mp.2014.66. Epub 2014 Jul 22. Review.

5.

Contributions of magnetic resonance spectroscopy to understanding development: potential applications in the study of adolescent alcohol use and abuse.

Cohen-Gilbert JE, Jensen JE, Silveri MM.

Dev Psychopathol. 2014 May;26(2):405-23. doi: 10.1017/S0954579414000030. Epub 2014 Mar 12. Review.

6.

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Schizophr Res. 2014 Feb;152(2-3):325-32. doi: 10.1016/j.schres.2013.12.013. Epub 2014 Jan 11. Review.

7.

N-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.

Mondino M, Brunelin J, Saoud M.

Front Psychiatry. 2013 Sep 5;4:99. doi: 10.3389/fpsyt.2013.00099. eCollection 2013.

8.

T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Bracken BK, Rouse ED, Renshaw PF, Olson DP.

Psychiatry Res. 2013 Aug 30;213(2):142-53. doi: 10.1016/j.pscychresns.2013.03.005. Epub 2013 Jun 12. Review.

9.

Metabolomic analysis reveals metabolic disturbance in the cortex and hippocampus of subchronic MK-801 treated rats.

Sun L, Li J, Zhou K, Zhang M, Yang J, Li Y, Ji B, Zhang Z, Zhu H, Yang L, He G, Gao L, Wei Z, Wang K, Han X, Liu W, Tan L, Yu Y, He L, Wan C.

PLoS One. 2013;8(4):e60598. doi: 10.1371/journal.pone.0060598. Epub 2013 Apr 5.

10.

The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenia's Etiology.

Dias AM.

Curr Neuropharmacol. 2012 Mar;10(1):2-11. doi: 10.2174/157015912799362742.

11.

Neurocognitive performance stability in a multiplex multigenerational study of schizophrenia.

Roalf DR, Gur RC, Almasy L, Richard J, Gallagher RS, Prasad K, Wood J, Pogue-Geile MF, Nimgaonkar VL, Gur RE.

Schizophr Bull. 2013 Sep;39(5):1008-17. doi: 10.1093/schbul/sbs078. Epub 2012 Aug 27.

12.

Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.

Lee MR, Denic A, Hinton DJ, Mishra PK, Choi DS, Pirko I, Rodriguez M, Macura SI.

Bioanalysis. 2012 Jul;4(14):1787-804. doi: 10.4155/BIO.12.129. Review.

13.

Metabolic pathways and activity-dependent modulation of glutamate concentration in the human brain.

Mangia S, Giove F, Dinuzzo M.

Neurochem Res. 2012 Nov;37(11):2554-61. doi: 10.1007/s11064-012-0848-4. Epub 2012 Jul 31. Review.

14.

Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder.

Rass O, Forsyth JK, Krishnan GP, Hetrick WP, Klaunig MJ, Breier A, O'Donnell BF, Brenner CA.

Schizophr Res. 2012 Apr;136(1-3):143-9. doi: 10.1016/j.schres.2012.01.003. Epub 2012 Jan 28.

15.

T2 measurement of J-coupled metabolites in the human brain at 3T.

Ganji SK, Banerjee A, Patel AM, Zhao YD, Dimitrov IE, Browning JD, Brown ES, Maher EA, Choi C.

NMR Biomed. 2012 Apr;25(4):523-9. doi: 10.1002/nbm.1767. Epub 2011 Aug 15.

16.

Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands.

Capizzano AA, Toscano JL, Ho BC.

Schizophr Res. 2011 Sep;131(1-3):4-10. doi: 10.1016/j.schres.2011.05.024. Epub 2011 Jun 25.

17.

New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats.

Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA, Nithianantharajah J, Oomen CA, Saksida LM.

Neuropharmacology. 2012 Mar;62(3):1191-203. doi: 10.1016/j.neuropharm.2011.04.011. Epub 2011 Apr 21. Review.

18.

Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.

de la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D, Ramírez-Bermúdez J, Graff-Guerrero A.

Neuropsychopharmacology. 2011 Aug;36(9):1781-91. doi: 10.1038/npp.2011.65. Epub 2011 Apr 20.

19.

Imaging genetics of structural brain connectivity and neural integrity markers.

Marenco S, Radulescu E.

Neuroimage. 2010 Nov 15;53(3):848-56. doi: 10.1016/j.neuroimage.2009.11.030. Epub 2009 Nov 22. Review.

20.

Optimized glutamate detection at 3T.

Hancu I.

J Magn Reson Imaging. 2009 Nov;30(5):1155-62. doi: 10.1002/jmri.21936.

Supplemental Content

Support Center